Table 1.
Participant characteristics
| All participants (n = 386) | PI-naive (n = 198) | PI-experienced (n = 188) | |
|---|---|---|---|
| Male sex, n (%) | 284 (74) | 155 (78) | 129 (69) |
| Age (years), median (IQR) | 42 (36–47) | 41 (35–48) | 42 (37–47) |
| Ethnicity, n (%) | |||
| white | 208 (55) | 108 (56) | 100 (54) |
| black | 137 (36) | 67 (35) | 70 (38) |
| other | 34 (9) | 19 (10) | 15 (8) |
| Mode of transmission, n (%) | |||
| MSM | 185 (51) | 95 (52) | 90 (50) |
| heterosexual | 154 (43) | 75 (41) | 79 (44) |
| injection drug use | 10 (3) | 3 (2) | 7 (4) |
| other | 12 (3) | 8 (4) | 4 (2) |
| Subtype, n (%) | |||
| A | 37 (10) | 17 (9) | 20 (11) |
| B | 208 (54) | 108 (55) | 100 (53) |
| C | 67 (17) | 37 (19) | 30 (16) |
| CRF02_AG | 32 (8) | 16 (8) | 16 (9) |
| other | 42 (11) | 20 (10) | 22 (12) |
| Calendar year of darunavir start, median (IQR) | 2009 (2008–10) | 2010 (2009–11) | 2009 (2008–10) |
| CD4+ cell count at darunavir start (cells/mm3), median (IQR) | 242 (90–460) | 248 (90–453) | 235 (88–460) |
| Viral suppression at darunavir start, n (%) | 28 (8) | 18 (10) | 10 (5) |
| HIV RNA at darunavir start (log10 copies/mL), median (IQR) | 4.3 (2.9–5.2) | 4.7 (2.8–5.5) | 4.1 (2.9–4.9) |
| Time from baseline test to darunavir start (days), median (IQR) | 51 (22–133) | 71 (21–460) | 43 (24–69) |
| Time from darunavir start to post-exposure test (days), median (IQR) | 211 (106–441) | 168 (68–370) | 270 (133–500) |
| Viral suppression, RNA ≤50 copies/mL, occurred prior to post-exposure test, n (%) | 171 (48) | 79 (44) | 92 (51) |
| Log10 drop in RNA if no viral suppression (log10 copies/mL), median (IQR) | 0.3 (−0.2–1.8) | 0.5 (−0.2–2.2) | 0.3 (−0.2–1.1) |
| HIV RNA at post-exposure test (log10 copies/mL), median (IQR) | 3.3 (2.4–4.5) | 3.2 (2.3–4.6) | 3.4 (2.6–4.5) |
Missing data: ethnicity (4 PI-naive, 3 PI-experienced); mode of transmission (17, 8); CD4+ cell count (23, 12); HIV RNA at start (22, 6); RNA measurement between darunavir and post-exposure test (20, 7); RNA at post-exposure test (19, 8).